Literature DB >> 17355496

Similarities and differences between chronic migraine and episodic migraine.

Anna Ferrari1, Sheila Leone, Anna Valeria Vergoni, Alfio Bertolini, Grazia Sances, Ciro Pio Rosario Coccia, Alessandra Ottani, Diego Pinetti, Emilio Sternieri.   

Abstract

OBJECTIVE: To quantify and characterize the similarities and the differences between chronic migraine (CM) patients with medication overuse and episodic migraine (EM) patients with only occasional analgesic use.
BACKGROUND: Population-level epidemiology, characteristics, mechanisms of chronic daily headache, and medication-overuse headache have been widely studied but patient characteristics have received less attention. Methods.-We compared sociodemographic data, family history, physiological and medical history, health services utilized, drugs taken/prescribed, and outcome of 2 groups of subjects: 150 patients, suffering from CM, complicated by probable medication-overuse headache (CM group), consecutively admitted during 2005 to the inpatients' ward of the Headache Centre of the University Hospital of Modena and Reggio Emilia, Italy, to undergo withdrawal from their overused medications; 100 patients suffering from EM, uncomplicated by medication overuse (EM group), consecutively referred to the outpatients' ward of the Headache Centre during November and December 2005.
RESULTS: All sociodemographic characteristics were significantly different between the 2 groups. As a whole, the CM group began to suffer from migraine earlier than the EM group. Drug and/or alcohol abuse was significantly higher among first-degree relatives of CM (19%) than of EM (6%) patients. The most frequent comorbid disorders were psychiatric (67%) and gastrointestinal diseases (43%) in the CM group, and allergies in the EM group (31%). Seventy percent of CM patients and 42% of EM patients were taking daily at least another drug, besides those for headache treatment. Most overused medications in the CM group were triptans (43%); the EM group used above all single NSAIDs (56%). At 3-month follow-up, prophylactic treatments reduced, by at least 50%, the frequency of headache in about three-fourths of patients of both the groups; however, headache remained significantly more frequent in the CM than in EM group: only a minority (15%) of CM patients reverted to a headache frequency comparable to that of the EM group.
CONCLUSIONS: CM patients present more multiple comorbid disorders, polypharmacy, and social impediments than EM patients. These associated conditions complicate CM clinical management. Even after withdrawal from medication overuse, CM could not be completely reverted by current prophylactic treatments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17355496     DOI: 10.1111/j.1526-4610.2006.00629.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  30 in total

1.  Genomic expression patterns in medication overuse headaches.

Authors:  Andrew D Hershey; Danny Burdine; Marielle A Kabbouche; Scott W Powers
Journal:  Cephalalgia       Date:  2010-06-02       Impact factor: 6.292

Review 2.  Animal models of chronic migraine.

Authors:  Robin James Storer; Weera Supronsinchai; Anan Srikiatkhachorn
Journal:  Curr Pain Headache Rep       Date:  2015-01

3.  Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache.

Authors:  Sarah Cargnin; Michele Viana; Grazia Sances; Marika Bianchi; Natascia Ghiotto; Cristina Tassorelli; Giuseppe Nappi; Pier Luigi Canonico; Armando A Genazzani; Salvatore Terrazzino
Journal:  Eur J Clin Pharmacol       Date:  2014-08-07       Impact factor: 2.953

Review 4.  Sleep in Patients with Chronic Migraine.

Authors:  Chun-Pai Yang; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2017-09

5.  Associations between migraine attacks and nightly sleep characteristics among adults with episodic migraine: a prospective cohort study.

Authors:  Angeliki Vgontzas; Wenyuan Li; Elizabeth Mostofsky; Michael Rueschman; Murray A Mittleman; Suzanne M Bertisch
Journal:  Sleep       Date:  2020-07-13       Impact factor: 5.849

6.  Predictive index for the onset of medication overuse headache in migraine patients.

Authors:  T Onaya; M Ishii; H Katoh; S Shimizu; H Kasai; M Kawamura; Y Kiuchi
Journal:  Neurol Sci       Date:  2013-01       Impact factor: 3.307

Review 7.  Mechanism of chronic migraine.

Authors:  Sheena K Aurora; Arun Kulthia; Patricia M Barrodale
Journal:  Curr Pain Headache Rep       Date:  2011-02

Review 8.  OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.

Authors:  James E Frampton
Journal:  Drugs       Date:  2012-04-16       Impact factor: 9.546

Review 9.  Focus on headache as an adverse reaction to drugs.

Authors:  Anna Ferrari; Luca Spaccapelo; Daniela Gallesi; Emilio Sternieri
Journal:  J Headache Pain       Date:  2009-06-04       Impact factor: 7.277

Review 10.  Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification.

Authors:  James A Charles; B L Peterlin; Alan M Rapoport; Steven L Linder; Marielle A Kabbouche; Fred D Sheftell
Journal:  J Headache Pain       Date:  2009-06-09       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.